WO2010103539A3 - Sustained release oral formulation of vinpocetine - Google Patents

Sustained release oral formulation of vinpocetine Download PDF

Info

Publication number
WO2010103539A3
WO2010103539A3 PCT/IN2010/000129 IN2010000129W WO2010103539A3 WO 2010103539 A3 WO2010103539 A3 WO 2010103539A3 IN 2010000129 W IN2010000129 W IN 2010000129W WO 2010103539 A3 WO2010103539 A3 WO 2010103539A3
Authority
WO
WIPO (PCT)
Prior art keywords
vinpocetine
sustained release
oral formulation
release oral
percent
Prior art date
Application number
PCT/IN2010/000129
Other languages
French (fr)
Other versions
WO2010103539A2 (en
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Original Assignee
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinesh Shantilal Patel, Sachin Dinesh Patel, Shashikant Prabhudas Kurani filed Critical Dinesh Shantilal Patel
Publication of WO2010103539A2 publication Critical patent/WO2010103539A2/en
Publication of WO2010103539A3 publication Critical patent/WO2010103539A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

A sustained release vinpocetine oral formulation comprising vinpocetine in the range of about 1 % to 25 %; about 30 to 70 percent by weight of cellulose ether; other components that includes a therapeutically inert, pharmaceutically acceptable adjunct material selected from the group consisting of water soluble fillers; from about 10 to about 30 percent by weight of acidifier; conventional ingredients selected from binders, lubricants and disintegrants and coating materials.
PCT/IN2010/000129 2009-03-09 2010-03-08 Sustained release oral formulation of vinpocetine WO2010103539A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN523MU2009 2009-03-09
IN523/MUM/2009 2009-03-09

Publications (2)

Publication Number Publication Date
WO2010103539A2 WO2010103539A2 (en) 2010-09-16
WO2010103539A3 true WO2010103539A3 (en) 2010-12-02

Family

ID=42728889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000129 WO2010103539A2 (en) 2009-03-09 2010-03-08 Sustained release oral formulation of vinpocetine

Country Status (1)

Country Link
WO (1) WO2010103539A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108564059B (en) * 2018-04-26 2021-02-23 歌尔科技有限公司 Wearable device, data processing method and device thereof, equipment and storage medium

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140118410A (en) * 2013-03-29 2014-10-08 초당약품공업 주식회사 Eperisone pharmaceutical composition enhancing storage and pH stability
JP6574556B2 (en) 2014-08-27 2019-09-11 日東電工株式会社 Intraoral film-form base and preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
JPH05262767A (en) * 1992-03-19 1993-10-12 Takeda Chem Ind Ltd Persistent preparation
WO1996025161A1 (en) * 1995-02-15 1996-08-22 Takeda Chemical Industries, Ltd. Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3479423D1 (en) 1984-02-29 1989-09-21 Covex Sa Citrate of vinpocetine, and process for its preparation
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
AU645003B2 (en) 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
EP0689844A1 (en) 1994-06-23 1996-01-03 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Complexes of vinpocetine formed with cyclodextrins, process for their preparation and pharmaceutical compositions containing them
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6572899B1 (en) 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
WO2007145993A2 (en) 2006-06-05 2007-12-21 Brite Age Modified compositions and methods for enhancing brain function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
JPH05262767A (en) * 1992-03-19 1993-10-12 Takeda Chem Ind Ltd Persistent preparation
WO1996025161A1 (en) * 1995-02-15 1996-08-22 Takeda Chemical Industries, Ltd. Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHINESE PHARMACEUTICAL JOURNAL 200406 CN, vol. 39, no. 6, June 2004 (2004-06-01), pages 442 - 446, ISSN: 1001-2494 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; June 2004 (2004-06-01), NIE S -F ET AL: "Influence of citric acid and pH value of dissolution medium on vinpocetine release from hydrophilic matrix tablets", XP002602978, Database accession no. EMB-2004416371 *
DATABASE WPI Week 199345, Derwent World Patents Index; AN 1993-357184, XP002602977 *
NIE S ET AL: "THE EFFECT OF CITRIC ACID ADDED TO HYDROXYPROPYL METHYLCELLULOSE (HPMC) MATRIX TABLETS ON THE RELEASE PROFILE OF VINPOCETINE", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US LNKD- DOI:10.1081/DDC-120037664, vol. 30, no. 6, 1 January 2004 (2004-01-01), pages 627 - 635, XP008076395, ISSN: 0363-9045 *
RIBEIRO L ET AL: "In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.JCONREL.2004.12.001, vol. 103, no. 2, 21 March 2005 (2005-03-21), pages 325 - 339, XP004823749, ISSN: 0168-3659 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108564059B (en) * 2018-04-26 2021-02-23 歌尔科技有限公司 Wearable device, data processing method and device thereof, equipment and storage medium

Also Published As

Publication number Publication date
WO2010103539A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
MY173715A (en) Delayed release, oral dosage compositions that contain amorphous cddo-me
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
WO2007097770A8 (en) Metoprolol succinate e.r. tablets and methods for their preparation
NZ599763A (en) Tablet formulations of neratinib maleate
WO2011106478A3 (en) Apixaban formulations
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
MX2010005889A (en) Novel thiophene derivatives.
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2011049309A3 (en) Pharmaceutical composition with both immediate and extended release characteristics
WO2010064126A3 (en) Controlled release dosage forms
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
WO2012085043A3 (en) Rapidly disintegrating, solid coated dosage form
WO2009100181A3 (en) Absorbent ingestible agents and associated methods of manufacture and use
WO2013062790A3 (en) Ascophyllum nodosum animal chews
WO2011107970A3 (en) Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect.
WO2012085927A3 (en) Tadalafil compositions
WO2008148080A8 (en) Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
WO2011143118A3 (en) Alcohol-resistant formulations
NZ603199A (en) Orally disintegrating tablet containing acarbose
MX2007013327A (en) Extended release formulations.
EP1798234A4 (en) Pharmaceutical composition comprising temozolomide ester
WO2010103539A3 (en) Sustained release oral formulation of vinpocetine
MX2010001243A (en) Anti-inflammatory composition.
WO2010039798A3 (en) Amorphous compositions of sunitinib base and l-malic acid

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10740753

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10740753

Country of ref document: EP

Kind code of ref document: A2